ciglitazone has been researched along with Alloxan Diabetes in 20 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Chronic administration of ADD-3878 for as long as 12 wk to young yellow KK mice, which were in the early stage of diabetes and obesity, depressed age-dependent rises in blood glucose, plasma triglyceride, and insulin without exerting any effect on obesity." | 5.27 | Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent. ( Fujita, T; Iwatsuka, H; Kawamatsu, Y; Sohda, T; Sugiyama, Y; Suzuoki, Z; Taketomi, S, 1983) |
| "Insulin resistance is a characteristic feature of type II diabetes as well as obesity." | 2.41 | [Discovery and development of a new insulin sensitizing agent, pioglitazone]. ( Fujita, T; Ikeda, H; Kawamatsu, Y; Meguro, K; Sohda, T, 2002) |
| " CZ ameliorated decrease bioavailability of NO in the diabetic animal." | 1.35 | Ciglitazone, a PPARgamma agonist, ameliorates diabetic nephropathy in part through homocysteine clearance. ( Kumar, M; Kundu, S; Rodriguez, WE; Sen, U; Tyagi, N; Tyagi, SC, 2008) |
| " Chronic administration of ADD-3878 for as long as 12 wk to young yellow KK mice, which were in the early stage of diabetes and obesity, depressed age-dependent rises in blood glucose, plasma triglyceride, and insulin without exerting any effect on obesity." | 1.27 | Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent. ( Fujita, T; Iwatsuka, H; Kawamatsu, Y; Sohda, T; Sugiyama, Y; Suzuoki, Z; Taketomi, S, 1983) |
| " To see the dose-response of insulin, a second experiment was carried out in which portions of the fat pads were incubated in vitro with glucose-1-14C in the presence of 0-40 ng/ml insulin and isolated adipocytes were used to estimate for 125I-insulin binding." | 1.27 | Ciglitazone, a new hypoglycemic agent. II. Effect on glucose and lipid metabolisms and insulin binding in the adipose tissue of C57BL/6J-ob/ob and -+/? mice. ( Chang, AY; Gilchrist, BJ; Wyse, BM, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (35.00) | 18.7374 |
| 1990's | 8 (40.00) | 18.2507 |
| 2000's | 5 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wrobel, J | 1 |
| Dietrich, A | 1 |
| Woolson, SA | 1 |
| Millen, J | 1 |
| McCaleb, M | 1 |
| Harrison, MC | 1 |
| Hohman, TC | 1 |
| Sredy, J | 1 |
| Sullivan, D | 1 |
| Kees, KL | 3 |
| Smith, TM | 1 |
| McCaleb, ML | 3 |
| Prozialeck, DH | 2 |
| Cheeseman, RS | 2 |
| Christos, TE | 2 |
| Patt, WC | 1 |
| Steiner, KE | 3 |
| Ellinboe, JW | 1 |
| Alessi, TR | 1 |
| Dolak, TM | 1 |
| Nguyen, TT | 1 |
| Tomer, JD | 1 |
| Guzzo, F | 1 |
| Bagli, JF | 1 |
| Sohda, T | 4 |
| Mizuno, K | 1 |
| Momose, Y | 2 |
| Ikeda, H | 3 |
| Fujita, T | 4 |
| Meguro, K | 3 |
| Caggiano, TJ | 1 |
| Fitzgerald, JJ | 1 |
| Kates, MJ | 1 |
| Kulishoff, JM | 1 |
| Moore, RD | 1 |
| Henke, BR | 1 |
| Blanchard, SG | 1 |
| Brackeen, MF | 1 |
| Brown, KK | 1 |
| Cobb, JE | 1 |
| Collins, JL | 1 |
| Harrington, WW | 1 |
| Hashim, MA | 1 |
| Hull-Ryde, EA | 1 |
| Kaldor, I | 1 |
| Kliewer, SA | 1 |
| Lake, DH | 1 |
| Leesnitzer, LM | 1 |
| Lehmann, JM | 1 |
| Lenhard, JM | 1 |
| Orband-Miller, LA | 1 |
| Miller, JF | 1 |
| Mook, RA | 1 |
| Noble, SA | 1 |
| Oliver, W | 1 |
| Parks, DJ | 1 |
| Plunket, KD | 1 |
| Szewczyk, JR | 1 |
| Willson, TM | 1 |
| Rodriguez, WE | 2 |
| Sen, U | 2 |
| Tyagi, N | 2 |
| Kumar, M | 2 |
| Carneal, G | 1 |
| Aggrawal, D | 1 |
| Newsome, J | 1 |
| Tyagi, SC | 3 |
| Kundu, S | 1 |
| Kawamatsu, Y | 3 |
| Reddy, HK | 1 |
| Koshy, SK | 1 |
| Wasson, S | 1 |
| Quan, EE | 1 |
| Pagni, S | 1 |
| Roberts, AM | 1 |
| Joshua, IG | 1 |
| Ohga, S | 1 |
| Shikata, K | 1 |
| Yozai, K | 1 |
| Okada, S | 1 |
| Ogawa, D | 1 |
| Usui, H | 1 |
| Wada, J | 1 |
| Shikata, Y | 1 |
| Makino, H | 1 |
| Kobayashi, M | 1 |
| Iwasaki, M | 1 |
| Ohgaku, S | 1 |
| Maegawa, H | 1 |
| Watanabe, N | 1 |
| Shigeta, Y | 1 |
| Sugiyama, Y | 2 |
| Taketomi, S | 2 |
| Iwatsuka, H | 1 |
| Suzuoki, Z | 1 |
| Chang, AY | 3 |
| Wyse, BM | 3 |
| Gilchrist, BJ | 3 |
| Peterson, T | 2 |
| Diani, AR | 2 |
| Sawada, GA | 1 |
| Hearron, AE | 1 |
| Gill, AM | 1 |
| Yen, TT | 1 |
| Yokono, K | 1 |
1 review available for ciglitazone and Alloxan Diabetes
| Article | Year |
|---|---|
[Discovery and development of a new insulin sensitizing agent, pioglitazone].
Topics: Animals; Clinical Trials as Topic; Clofibrate; Diabetes Mellitus; Diabetes Mellitus, Experimental; D | 2002 |
19 other studies available for ciglitazone and Alloxan Diabetes
| Article | Year |
|---|---|
Novel spirosuccinimides with incorporated isoindolone and benzisothiazole 1,1-dioxide moieties as aldose reductase inhibitors and antihyperglycemic agents.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Cattle; Diabetes Mellitus, Experimental; Glyceraldehyde; | 1992 |
Perfluorocarbon-based antidiabetic agents.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Female; Fluorocarbons; Hypoglycemic Agents; | 1992 |
Antihyperglycemic activity of novel substituted 3H-1,2,3,5-oxathiadiazole 2-oxides.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Male; Mice; Mice, Inbr | 1992 |
Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents.
Topics: Animals; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resista | 1992 |
Perfluoro-N-[4-(1H-tetrazol-5-ylmethyl)phenyl]alkanamides. A new class of oral antidiabetic agents.
Topics: Administration, Oral; Anilides; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Hydrocarbon | 1989 |
Studies on new acidic azoles as glucose-lowering agents in obese, diabetic db/db mice.
Topics: Animals; Azoles; Blood Glucose; Diabetes Mellitus, Experimental; Hydrogen-Ion Concentration; Hypogly | 1995 |
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
Topics: Administration, Oral; Aminopyridines; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Experime | 1998 |
PPAR gamma agonist normalizes glomerular filtration rate, tissue levels of homocysteine, and attenuates endothelial-myocyte uncoupling in alloxan induced diabetic mice.
Topics: Alloxan; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Endothelium; Glomerular Filtration | 2008 |
Ciglitazone, a PPARgamma agonist, ameliorates diabetic nephropathy in part through homocysteine clearance.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Epinephrine; Gene E | 2008 |
Adaptive-outward and maladaptive-inward arterial remodeling measured by intravascular ultrasound in hyperhomocysteinemia and diabetes.
Topics: Animals; Collagen; Coronary Artery Disease; Coronary Vessels; Diabetes Complications; Diabetes Melli | 2006 |
Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation.
Topics: Anilides; Animals; Anti-Inflammatory Agents; Cells, Cultured; Collagen Type IV; Diabetes Mellitus, E | 2007 |
A new potentiator of insulin action. Post-receptor activation in vitro.
Topics: Adipose Tissue; Animals; Biological Transport, Active; Blood Glucose; Body Weight; Deoxyglucose; Dia | 1983 |
Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent.
Topics: Animals; Blood Glucose; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Experimental; Dogs; Fatty | 1983 |
Ciglitazone, a new hypoglycemic agent. I. Studies in ob/ob and db/db mice, diabetic Chinese hamsters, and normal and streptozotocin-diabetic rats.
Topics: Animals; Blood Glucose; Cricetinae; Cricetulus; Diabetes Mellitus, Experimental; Fatty Acids, Nonest | 1983 |
Ciglitazone, a new hypoglycemic agent. II. Effect on glucose and lipid metabolisms and insulin binding in the adipose tissue of C57BL/6J-ob/ob and -+/? mice.
Topics: Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Fatty Acids, Nonesterified; | 1983 |
Ciglitazone, a new hypoglycaemic agent. 4. Effect on pancreatic islets of C57BL/6J-ob/ob and C57BL/KsJ-db/db mice.
Topics: Animals; Blood Glucose; Cytoplasmic Granules; Diabetes Mellitus, Experimental; Hypoglycemic Agents; | 1984 |
Effects of ciglitazone on endogenous plasma islet amyloid polypeptide and insulin sensitivity in obese-diabetic viable yellow mice.
Topics: Amyloid; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Insulin; Isle | 1991 |
Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones.
Topics: Animals; Chemical Phenomena; Chemistry; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Male; | 1990 |
Insulin receptor and postbinding defects in KK mouse adipocytes and improvement by ciglitazone.
Topics: 3-O-Methylglucose; Adipose Tissue; Animals; Carbon Radioisotopes; Cells, Cultured; Diabetes Mellitus | 1988 |